Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer

BACKGROUND AND OBJECTIVE: Several clinical trials have proven that icotinib hydrochloride, a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemot...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Onco Targets Ther
Main Authors: Shen, Yan-Wei, Zhang, Xiao-Man, Li, Shu-Ting, Lv, Meng, Yang, Jiao, Wang, Fan, Chen, Zhe-Ling, Wang, Bi-Yuan, Li, Pan, Chen, Ling, Yang, Jin
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2016
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771396/
https://ncbi.nlm.nih.gov/pubmed/26966381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S98363
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker